

MAY 0 7 2002

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Clark Smith Vice President Sultan Chemists, Incorporated 85 West Forest Avenue Englewood, New Jersey 07631

Re: K020612

Trade/Device Name: Sultan Sporox Test Vial, Model 75195

Regulation Number: 880.2800 and 880.6885

Regulation Name: Sterilization Process Indicator and Liquid Chemical

Sterilants/High Level Disinfectants

Regulatory Class: II

Product Code: JOJ and MED Dated: February 20, 2002 Received: February 25, 2002

Dear Mr. Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements

of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4618. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours.

Timothy A. Ulatowski

Director

Division of Dental, Infection Control and General Hospital Devices Office of Device Evaluation Center for Devices and Radiological Health

Statement of Indications For Use

				Page1_	of1
510(k) Number: <u>K</u>	020612				
Device Name:	Sultan Sporox Te	est Vial			
Indications For Use:	Sultan Sporox' method for determined is pressulted. The Sport hydrogen perox sterilization	ermining sent in S porox Te	if an effective porox Sterilizest Vials indic	e concentration ing and Dising at the concer	on of hydrogen fecting ntration of
PLEASE DO NOT WRI	 				E IF NEEDED
Col	ncurrence of CDRH,	Оппсе от	Device Evaluation	on (ODE)	
Prescription Use (Per 21 CFR 801.109		or	Over-the-Cou	nter Use	
	(Division Sign-O Division of Denta and General Hos	l lofo at	on Control, ices		